DiaMedica Therapeutics, Inc.

  • Home
  • Our Focus
    • Overview
    • Literature & Publications
  • Pipeline
    • Overview
    • Preeclampsia & Fetal Growth Restriction
    • Acute Ischemic Stroke
  • Clinical Trials
    • Overview
    • Preeclampsia & Fetal Growth Restriction
    • Acute Ischemic Stroke
  • ReMEDy2 Trial
    • Overview
    • About ReMEDy2
    • Stroke Disease
    • For Physicians
    • Trial Locations
  • About DiaMedica
    • Overview
    • Leadership
    • Careers
    • Contact
  • Investors Relations
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Data
    • Analyst Coverage
    • Financial Reports & SEC Filings
    • Governance
    • Resources

Press Releases

Investors Relations

Investors Relations

  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Data
    • Nasdaq Quote
    • Charts
    • Historical Data
  • Analyst Coverage
  • Financial Reports & SEC Filings
    • SEC Filings
    • Annual Reports
    • Tax Information (PFIC)
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • Investor Contact
    • FAQ
    • Share Consolidation Instructions
    • Email Alerts
Aug 08, 2023 8:32am EDT

DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023

Jul 18, 2023 8:30am EDT

DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference

Jun 26, 2023 8:30am EDT

DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement

Jun 21, 2023 8:39am EDT

DiaMedica Therapeutics Announces $37.5 Million Private Placement

Jun 21, 2023 8:15am EDT

DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke

May 30, 2023 8:29am EDT

DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors

May 15, 2023 4:28pm EDT

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results

May 08, 2023 8:50am EDT

DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023

Apr 11, 2023 8:41am EDT

DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer

Mar 28, 2023 4:30pm EDT

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …17
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2025 DiaMedica Therapeutics, Inc. All Rights Reserved.
Twitter LinkedIn
Privacy Policy Disclaimer Sitemap